Anthony F. Martin, Ph.D has more than 25 years' experience in leading and providing life science and biotechnology companies counsel on a range of strategic, management and funding matters. Dr. Martin is the Founder and Managing Partner of TMA Consultants, an organization that specializes in providing Interim management and Directorship guidance for high tech medical companies. Dr. Martin has a history of delivering shareholder value and most recently served as Chairman of Molecular Insight Pharmaceuticals Inc. a NASDAQ quoted biopharma Company specialising in new radiotherapies for heart disease and cancer. He was also Non-Executive Director of Prelude Trust plc, an investment trust that specialized in early-stage, technology-based businesses; and as Chairman of NeuTec Pharma plc, played a pivotal role in guiding the biopharmaceutical company’s listing on the AIM market in the United Kingdom and its subsequent sale to Novartis. Dr. Martin has also held senior positions in a number of well-known life science companies both in the United Kingdom and United States including: Managing Director of British Biotech Products Ltd, Chairman, President and CEO of Molecular Probes which he sold to Invitrogen Corporation in 2003 , President of Molecular Biology, Invitrogen Corporation where he led the acquisition and subsequent integration of Life Technologies, Chairman and CEO of AZUR Environmental, CEO of Celsis International plc which he took public in 1992, as well as senior leadership roles at Amersham International plc.
Dr. Martin holds a Ph.D. in Immunology and a first class honors degree in Applied Chemistry from the Universities of Manchester and Huddersfield, UK.
Dr. Martin is currently Chairman of Immunodiagnostic Systems Holdings plc., Sphere Medical Holding plc., Phico Therapeutics Ltd., and a Non Executive Director of Abcam plc, and Orthofix International NV.